Highlights Ayala Pharmaceuticals, Inc.

Equities

ADXS

US0076244062

Market Closed - OTC Markets Other stock markets 01:35:48 2024-04-29 pm EDT			5-day change	1st Jan Change
0.665 ^USD	+19.82%		+16.26%	-0.30%

Apr. 16	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 16	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	Mar. 24	CI
North American Morning Briefing : Fed's Preferred -2-	Feb. 29	DJ
North American Morning Briefing : Nvidia Ignites -2-	Feb. 22	DJ
Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid Tumors	Feb. 20	CI
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	Feb. 06	MT
Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million.	Feb. 05	CI
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023	23-10-23	CI
BioSight Ltd. acquired Ayala Pharmaceuticals, Inc. in a reverse merger transaction.	23-10-17	CI
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
BioSight Ltd. entered into a definitive merger agreement to acquire Ayala Pharmaceuticals, Inc. in a reverse merger transaction.	23-07-26	CI
Ayala Pharmaceuticals, Inc. entered into a definitive merger agreement to acquire BioSight Ltd from Israel Biotech Fund, BioTelemetry, Inc., Arkin Bio Venture Partners Ltd., Primera Capital, SBI JI Innovation Advisory Ltd., Migdal Insurance Company Ltd., The Phoenix Insurance Company Ltd. and others.	23-07-26	CI
North American Morning Briefing : Earnings Optimism Continues to Support Stocks	23-07-19	DJ
North American Morning Briefing : Traders Bet Data to Show Cooling Inflation	23-07-12	DJ
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors	23-07-05	CI
Ayala Pharmaceuticals, Inc. Updates RINGSIDE Phase 2 Results Featured in Poster Discussion Session At 2023 American Society of Clinical Oncology Annual Meeting	23-06-05	CI
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ayala Pharmaceuticals, Inc.

Equities

ADXS

US0076244062

Highlights

Filters